STOCK TITAN
  1. Home
  2. News
  3. BRTX

Biorestorative Therapies Inc - BRTX STOCK NEWS

Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.

BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.

Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.

Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.

Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.

News

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Rhea-AI Summary

BioRestorative Therapies, Inc. (

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
none
-
News

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Rhea-AI Summary
BioRestorative Therapies announces FDA clearance of Phase 2 BRTX-100 clinical study protocol amendment, replacing saline injections with sham injections in the control group. The amendment aims to enhance safety and prevent transient clinical outcomes, maintaining the 2024 enrollment completion target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
clinical trial
-
News

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Rhea-AI Summary
BioRestorative Therapies, Inc. announces collaboration with Galen Patient Recruitment, Inc. to accelerate patient enrollment in Phase 2 study of BRTX-100 for chronic lumbar disc disease. Recent enhancements triple monthly trial capacity, with enrollment expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
partnership clinical trial
News

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Rhea-AI Summary
BioRestorative Therapies, Inc. announces the filing of a registration statement on Form S-1 with the SEC for the resale of up to 2,513,686 shares of common stock by selling securityholders. The filing covers shares issuable pursuant to previously issued warrants, with the registration statement not yet effective. The Company is not offering shares directly to the public at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
-
News

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Rhea-AI Summary
BioRestorative Therapies, Inc. announced the filing of its Form 10-K annual report for 2023, highlighting its lead clinical-stage cell therapy candidate, BRTX-100, and ThermoStem® program. Positive preliminary data from the Phase 2 study of BRTX-100 in treating chronic lumbar disc disease was presented, showing encouraging results. The company also received four notices of allowance for its ThermoStem® program, indicating progress in patent approvals. Financially, BioRestorative reported a net loss decrease of 22% for 2023, with $11.07 million in cash, cash equivalents, and investments at year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
News

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Rhea-AI Summary
BioRestorative Therapies, Inc. announces its participation in the 36th Annual ROTH Conference. The company's CEO will engage in a fireside chat and one-on-one meetings with investors. The event will be held from March 17-19, 2024, at the Ritz Carlton, Laguna Niguel in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
News

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

Rhea-AI Summary
BioRestorative Therapies (BRTX) is advancing its lead candidate, BRTX-100, a cell-based therapy for chronic lumbar disc disease. The recent data presented at the ORS 2024 Annual Meeting showed positive trends in pain and function improvements. The therapy uses autologous stem cells manufactured in a low oxygen environment to mimic disc conditions. If successful, BRTX-100 could revolutionize disc-related pain treatment with its personalized, minimally invasive approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
News

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

Rhea-AI Summary
BioRestorative Therapies, Inc. announced agreements with certain holders of its existing warrants to exercise their warrants at a reduced price, generating approximately $8.1 million in gross proceeds. The reduction of the exercise price and issuance of new warrants was structured as an at-market transaction under Nasdaq rules. The new warrants will be exercisable into an aggregate of up to 2,513,685 shares of common stock, at an exercise price of $2.43 per share, and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.49%
Tags
none
-
News

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary 26 and 52-week blinded data from the ongoing Phase 2 clinical trial of their lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease. The data presented at the Orthopaedic Research Society 2024 Annual Meeting showed positive trends in pain and function scales compared to baseline, indicating meaningful signals in patients enrolled in the study. The company also reported no notable safety signals, and the FDA will use the data to determine whether the trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.21%
Tags
clinical trial
News

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary blinded data from the ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease. The data will be presented at the Orthopaedic Research Society 2024 Annual Meeting. BRTX-100 is a novel cell-based therapeutic evaluated for safety and efficacy in treating cLDD. The company will host a webcasted conference call to review the data on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.52%
Tags
conferences clinical trial
Stock BRTX logo
Biorestorative Therapies Inc

Nasdaq:BRTX

BRTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BRTX Stock Data

12.11M
5.59M
27.7%
13.91%
10.35%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States
MELVILLE